Home/Pipeline/APA-1000 Breast Thermotherapy System

APA-1000 Breast Thermotherapy System

Breast Cancer

Phase IIIPivotal Trial Approved (IDE/ITA)NCT01204801

Key Facts

Indication

Breast Cancer

Phase

Phase III

Status

Pivotal Trial Approved (IDE/ITA)

Company

Medifocus

About Medifocus

Medifocus Inc. is a public medical technology company with a mission to improve standards of care through its proprietary focused heat platforms. Its strategy leverages a revenue-generating, FDA-approved device for BPH (Prolieve®) to fund the clinical development of its late-stage Adaptive Phased Array (APA-1000) system for breast cancer. The company has established a robust intellectual property portfolio with approximately 100 patents and has secured regulatory approvals to initiate a pivotal Phase III trial for its oncology asset.

View full company profile

Therapeutic Areas

Oncology Urology

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
Undisclosed	Biossil	Phase 2/3	Active